Community Contributor
Member since 2026
Views
0 Total number of views
Fair Values Set
0 Total number of fair values set
Comments
0 Total number of comments
Followers
0 Total number of followers

No bio added yet

No link added
AUPH logo
Aurinia Pharmaceuticals

Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche

Aurinia Pharmaceuticals (NASDAQ: AUPH) continues to prove that clarity can outperform complexity. With Lupkynis (voclosporin) as its single commercial asset for lupus nephritis , the company has turned concentration into discipline.Read more

View narrative
US$16.29
0.4% undervalued intrinsic discount
Fair Value
Revenue
13% p.a.
Profit Margin
68%
Future PE
7x
Price in 2031
US$22.85